Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
Hoffmann-La Roche
380 participants
Jun 23, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive cevostamab IV as per the schedule given in the protocol.
Participants will receive pomalidomide tablet orally PO as per the schedule given in the protocol.
Participants will receive dexamethasone tablet orally PO or IV as per the schedule given in the protocol.
Participants will receive daratumumab SC as per the schedule given in the protocol.
Participants will receive elotuzumab IV as per the schedule given in the protocol.
Participants will receive carfilzomib IV as per the schedule given in the protocol.
Locations(75)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07555938